Corcept Therapeutics, Inc. (CORT) Reports Q3 EPS Loss of $0.08
Tweet
Share
E-mailGet Alerts CORT Hot Sheet
Price: $113.76 +3.15%
EPS Growth %: +406.3%
Financial Fact:
Net loss and comprehensive loss: 2.59M
Today's EPS Names:
ALZN, ASPU, OCCI, More
EPS Growth %: +406.3%
Financial Fact:
Net loss and comprehensive loss: 2.59M
Today's EPS Names:
ALZN, ASPU, OCCI, More
Join SI Premium – FREE
Corcept Therapeutics, Inc. (NASDAQ: CORT) reported Q3 EPS of ($0.08), $0.02 better than the analyst estimate of ($0.10).
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU panel recommends approval of Corcept's relacorilant for ovarian cancer
- Kestra Medical Technologies, Ltd. (KMTS) Reports Q1 Loss of $0.75/sh
- Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
